Compare Illinois Tool Works Inc. (ITW) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Smith & Nephew plc — how do they compare? Illinois Tool Works Inc. trades at $264.18 (market cap $74.38B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: Illinois Tool Works Inc. is far larger — about 6.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 67 Days and Smith & Nephew plc for 120 Days on average.
| ITW | SNN | |
|---|---|---|
Market Cap | $74.38B | $11.10B |
Volume | 1,125,477 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $299.60 | $37.17 |
52-Week Low | $241.07 | $26.42 |
Typical Hold Time | 67 Days | 120 Days |
Enterprise Value | $83.23B | $14.13B |
Dividend Yield | 2.63% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $261.15, down 2.24% on the day, with a bearish technical signal from moving averages. The company demonstrates strong profitability with a 19.39% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights its status as a Dividend King, having raised its dividend to $1.72 per share, with a forward yield of approximately 2.57%.
The outlook is mixed; strong fundamentals and a consensus price target of $280.14 suggest upside potential, but a high P/E ratio of 23.65 and bearish technical indicators indicate near-term pressure. Key risks include economic sensitivity and rising debt levels, while institutional buying provides some support.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
